LOGIN  |  REGISTER
Chimerix

Nyxoah: Information on the Total Number of Voting Rights and Shares

July 27, 2023 | Last Trade: US$5.71 0.37 -6.09

Mont-Saint-Guibert (Belgium), July 27, 2023, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  • Share capital: EUR 4,924,151.05
  • Total number of securities carrying voting rights: 28,663,985 (all ordinary shares)
  • Total number of voting rights (= denominator): 28,663,985 (all relating to ordinary shares)
  • Number of rights to subscribe to securities carrying voting rights not yet issued:
  • 20 “2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 10,000 securities carrying voting rights (all ordinary shares);
  • 100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);
  • 410,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 410,500 securities carrying voting rights (all ordinary shares); and
  • 1,267,000 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,267,000 securities carrying voting rights (all ordinary shares); and
  • 700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it. 
+1 310 310 1313

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page